Drawing for PAPA & BARKLEY

USPTO serial 88977775

PAPA & BARKLEY

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
SALES, HEATHER ALISON
Law office
TMO LAW OFFICE 130 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with PAPA & BARKLEY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Thomas F. Zuber

Thomas F. Zuber ZUBER LAWLER LLP350 S. GRAND AVE., 32ND FLOORLOS ANGELES, CA 90071UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Mentholated ointment for medical use, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Medicated skin oils, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Topical analgesics, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Analgesic balm, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Medicated skin creams and lotions, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; medicated skin care preparations, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; medicated herbal topical creams, gels, skin sprays, balms, liniment and ointments, all the foregoing for the relief of pain, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Topical gel for medical and therapeutic treatment of minor aches and pains of muscles and joints, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Herbal tinctures for medical purposes, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all of the foregoing containing only naturally-occurring levels of CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Medicated oral spray for pain, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Pharmaceutical, medicinal, medicated herbal, medicated botanical, and medicated preparations in the form of salves, concentrates, pastes, extracts, tinctures, and mucous membrane doses, for use in connection with pain, muscle tension, muscle spasms, and gastrointestinal illness, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient, all of the foregoing containing no cannabis and no cannabinoids, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic Act; Muscle soaks, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, all the foregoing not including any products noncompliant with the U.S. Food Drug and Cosmetic ActACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Oct 18, 2022MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 18, 2022MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 18, 2022ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 26, 2022GNS1NOTIFICATION OF SUBSEQUENT FINAL EMAILED—
Mar 26, 2022GNSFSUBSEQUENT FINAL EMAILED—
Mar 26, 2022CFRCSUBSEQUENT FINAL REFUSAL WRITTEN—
Sep 29, 2021DPCCDIVISIONAL PROCESSING COMPLETE—
Sep 24, 2021DRRRDIVISIONAL REQUEST RECEIVED—
Sep 24, 2021ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Jun 5, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 4, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 4, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 10, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 10, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 10, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 7, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 7, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 7, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 15, 2020GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jun 15, 2020GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 15, 2020CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 12, 2020MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 11, 2020DPCCDIVISIONAL PROCESSING COMPLETE—
May 11, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 11, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 4, 2020ALIEASSIGNED TO LIE—
Apr 29, 2020DRRRDIVISIONAL REQUEST RECEIVED—
Apr 29, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 29, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 29, 2020ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Oct 29, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 29, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 29, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 28, 2019DOCKASSIGNED TO EXAMINER—
May 6, 2019DOCKASSIGNED TO EXAMINER—
May 6, 2019DOCKASSIGNED TO EXAMINER—
Mar 21, 2019MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 15, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 28, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance